R.P. Scherer selegiline Zydis wafer NDA to be filed in early 1996, softgel maker tells UBS meeting.
R.P. SCHERER SELEGILINE ZYDIS NDA SUBMISSION IN EARLY 1996 will be the first "therapeutically-enhanced generic" to be registered at FDA by the company's Advanced Therapeutics Products group, R.P. Scherer Chief Financial Officer Nicole Williams told analysts Oct. 18 in Manhattan at the UBS Securities Life Sciences Conference. Scherer's ATP "will be taking generic drugs, placing them in Scherer drug delivery systems, and taking them through the clinical and regulatory stages to the marketplace," Williams said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth